Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Orthofix Medical Inc. (OFIX)

Orthofix Medical shareholders elect 10 directors, approve 1.25 million more plan shares

Neutral Impact 2 of 5 shareholder Written later

At its June 10, 2026 annual meeting, Orthofix Medical shareholders elected all 10 director nominees to one-year terms, approved an advisory vote on executive compensation, ratified Ernst & Young LLP as auditor for 2026, and approved Amendment No. 5 to the Second Amended and Restated Stock Purchase Plan. The plan amendment adds 1,250,000 shares available for issuance under the plan, in which the company's named executive officers participate. The filing reports no other changes to the plan.

Key points

  • Ten directors were elected for terms ending at the 2027 annual meeting; Wayne Burris and Michael E. Paolucci each drew more than 5 million votes against.
  • Stock purchase plan amendment adds 1,250,000 shares; approved by 29,235,005 votes for and 831,625 against.
  • Executive compensation advisory vote passed with 24,480,474 votes for and 5,577,200 against.
  • Ernst & Young LLP ratified as independent auditor for the year ending December 31, 2026, with 33,262,505 votes for.

The filing

CompanyOrthofix Medical Inc. (OFIX)
Form8-K, current report
Filed with the SECJun 11, 2026, 7:01 AM ET
Accession number0001193125-26-266679

Items reported: 5.02 Director / Officer Change5.07 Shareholder Vote Results

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:28 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 11, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.